LENZ Q2 2026 revenue $5.5M, net loss $31.9M; VIZZ launch shows strong refill trends

LENZ Therapeutics, Inc.

Q2 total revenue $5.5M: product sales $1.7M (~27k packs) + license revenue $3.8M (incl. $2.5M Théa milestone, $1.25M Everest sublicense).
Net loss $31.9M for Q2 ($1.02/share) vs $14.9M loss ($0.53/share) in Q2 2025; SG&A up to $39.4M on launch investment.
Over 60% of ePharmacy patients bought multiple packs; Q4'25/Q1'26 cohorts tracking to 5 packs/year; >13,000 unique prescribers, ~75% repeat.
Cash $220.0M as of June 30, 2026; launched telehealth in July 2026 and nationwide TV ads with Sarah Jessica Parker.
Regulatory progress: MAA to UK MHRA, Health Canada NDS filed, Arrotex deal for Australia/NZ, Everest sublicense for Greater China.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.